FDA’s ‘Access’ Challenge Highlighted At Naloxone Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
‘Behind-the-counter’ placement of opioid overdose treatment doesn’t resonate with agency, even as it wants to broaden availability.